Enhancement of the anticancer effect of atorvastatin-loaded nanoemulsions by improving oral absorption via multivalent intestinal transporter-targeting lipids

References

• Bjarnadottir O, Kimbung S, Johansson I, et al. (2015). Global transcriptional changes following statin treatment in breast cancer. Clin Cancer Res 21:3402–11.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. (1974). Suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and inhibition of growth of human fibroblasts by 7-ketocholesterol. J Biol Chem 249:7306–14.
   PubMed Web of Science ®Google Scholar
• Buhaescu I, Izzedine H. (2007). Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40:575–84.
   PubMed Web of Science ®Google Scholar
• Buranrat B, Suwannaloet W, Naowaboot J. (2017). Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells. Oncol Lett 14:6243–50.
   PubMed Web of Science ®Google Scholar
• Chen J, Liu B, Yuan J, et al. (2012). Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production. Mol Oncol 6:62–72.
   PubMed Web of Science ®Google Scholar
• Chuang EY, Lin KJ, Su FY, et al. (2013). Calcium depletion-mediated protease inhibition and apical-junctional-complex disassembly via an EGTA-conjugated carrier for oral insulin delivery. J Control Release 169:296–305.
   PubMed Web of Science ®Google Scholar
• Collnot EM, Baldes C, Schaefer UF, et al. (2010). Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm 7:642–51.
   PubMed Web of Science ®Google Scholar
• Deng F, Bae YH. (2020). Bile acid transporter-mediated oral drug delivery. J Control Release 327:100–16.
   PubMed Web of Science ®Google Scholar
• Dulak J, Józkowicz A. (2005). Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 5:579–94.
   PubMed Web of Science ®Google Scholar
• Elmowafy M, Ibrahim HM, Ahmed MA, et al. (2017). Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Deliv 24:932–41.
   PubMed Web of Science ®Google Scholar
• El-Zailik A, Cheung LK, Wang Y, et al. (2019). Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery. J Pharm Biomed Anal 164:258–67.
   PubMed Web of Science ®Google Scholar
• Endo A, Tsujita Y, Kuroda M, et al. (1977). Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Eur J Biochem 77:31–6.
   PubMedGoogle Scholar
• Fuchs D, Berges C, Opelz G, et al. (2008). HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem Biophys Res Commun 374:309–14.
   PubMed Web of Science ®Google Scholar
• Gazzerro P, Proto MC, Gangemi G, et al. (2012). Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64:102–46.
   PubMed Web of Science ®Google Scholar
• Guo L, Zheng J, Zeng H, et al. (2020). Atorvastatin potentiates the chemosensitivity of human liver cancer cells to cisplatin via downregulating YAP1. Oncol Lett 21:1–8.
   PubMedGoogle Scholar
• He M, Guo S, Li Z. (2015). In situ characterizing membrane lipid phenotype of breast cancer cells using mass spectrometry profiling. Sci Rep 5:11298.
   PubMed Web of Science ®Google Scholar
• Ishak RA, Osman R. (2015). Lecithin/TPGS-based spray-dried self-microemulsifying drug delivery systems: in vitro pulmonary deposition and cytotoxicity. Int J Pharm 485:249–60.
   PubMed Web of Science ®Google Scholar
• Jain K, Kumar R, Sood S, et al. (2013). Enhanced oral bioavailability of Atorvastatin via oil-in-water nanoemulsion using aqueous titration method. J Pharm Sci Res 5:18–25.
   Google Scholar
• Jha SK, Chung JY, Pangeni R, et al. (2020a). Enhanced antitumor efficacy of bile acid-lipid complex-anchored docetaxel nanoemulsion via oral metronomic scheduling. J Control Release 328:368–94.
   PubMed Web of Science ®Google Scholar
• Jha SK, Han HS, Subedi L, et al. (2020b). Enhanced oral bioavailability of an etoposide multiple nanoemulsion incorporating a deoxycholic acid derivative-lipid complex. Drug Deliv 27:1501–13.
   PubMed Web of Science ®Google Scholar
• Jiang P, Mukthavaram R, Chao Y, et al. (2014). In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer 111:1562–71.
   PubMed Web of Science ®Google Scholar
• Jones HM, Fang Z, Sun W, et al. (2017). Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. Am J Cancer Res 7:2478–90.
   PubMed Web of Science ®Google Scholar
• Kang M, Jeong CW, Ku JH, et al. (2014). Inhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro. Int J Mol Sci 15:8106–21.
   PubMed Web of Science ®Google Scholar
• Khan FN, Dehghan MH. (2011). Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. AAPS PharmSciTech 12:1077–86.
   PubMed Web of Science ®Google Scholar
• Kirtane AR, Kalscheuer SM, Panyam J. (2013). Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv Drug Deliv Rev 65:1731–47.
   PubMed Web of Science ®Google Scholar
• Kusama T, Mukai M, Tatsuta M, et al. (2006). Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. Int J Oncol 29:217–23.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim JS, Kim Y. (2021). Atorvastatin-mediated rescue of cancer-related cognitive changes in combined anticancer therapies. PLoS Comput Biol 17:e1009457–28.
   PubMed Web of Science ®Google Scholar
• Li M, Wang Q, Li Y, et al. (2020). Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges. Pharmacol Ther 212:1–23.
   Web of Science ®Google Scholar
• Longo J, van Leeuwen JE, Elbaz M, et al. (2020). Statins as anticancer agents in the era of precision medicine. Clin Cancer Res 26:5791–800.
   PubMed Web of Science ®Google Scholar
• Ma Q, Gao Y, Xu P, et al. (2019). Atorvastatin inhibits breast cancer cells by downregulating PTEN/AKT pathway via promoting Ras homolog family member B (RhoB). Biomed Res Int 2019:3235021–15.
   PubMed Web of Science ®Google Scholar
• Maher S, Brayden DJ, Casettari L, et al. (2019). Application of permeation enhancers in oral delivery of macromolecules: an update. Pharmaceutics 11:41.
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. (2000). Current perspectives on statins. Circulation 101:207–13.
   PubMed Web of Science ®Google Scholar
• Marti JLG, Beckwitt CH, Clark AM, et al. (2021). Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer. Br J Cancer 125:1285–98.
   PubMed Web of Science ®Google Scholar
• Martinez TA, Zeybek ND, Müftüoğlu S. (2018). Evaluation of the cytotoxic and autophagic effects of atorvastatin on MCF-7 breast cancer cells. Balkan Med J 35:256–62.
   PubMed Web of Science ®Google Scholar
• Martínez-Botas J, Ferruelo AJ, Suarez Y, et al. (2001). Dose-dependent effects of lovastatin on cell cycle progression. Distinct requirement of cholesterol and non-sterol mevalonate derivatives. Biochim Biophys Acta 1532:185–94.
   PubMed Web of Science ®Google Scholar
• Nishida S, Matsuoka H, Tsubaki M, et al. (2005). Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Mol Cell Biochem 269:109–14.
   PubMed Web of Science ®Google Scholar
• Pangeni R, Kang S, Jha SK, et al. (2021). Intestinal membrane transporter-mediated approaches to improve oral drug delivery. J Pharm Investig 51:137–58.
   Web of Science ®Google Scholar
• Pangeni R, Subedi L, Jha SK, et al. (2020). Improvements in the oral absorption and anticancer efficacy of an oxaliplatin-loaded solid formulation: pharmacokinetic properties in rats and nonhuman primates and the effects of oral metronomic dosing on colorectal cancer. Int J Nanomedicine 15:7719–43.
   PubMed Web of Science ®Google Scholar
• Pisanti S, Picardi P, Ciaglia E, et al. (2014). Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res 88:84–98.
   PubMed Web of Science ®Google Scholar
• Plaza-Oliver M, Santander-Ortega MJ, Lozano MV. (2021). Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Deliv Transl Res 11:471–97.
   PubMed Web of Science ®Google Scholar
• Sarangi B, Jana U, Sahoo J, et al. (2018). Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology. Biomed Microdevices 20:1–12.
   Web of Science ®Google Scholar
• Sethunath V, Hu H, De Angelis C, et al. (2019). Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer. Mol Cancer Res 17:2318–30.
   PubMed Web of Science ®Google Scholar
• Shamsuddin, Fazil M, Ansari SH, Ali J, et al. (2016). Atorvastatin solid dispersion for bioavailability enhancement. J Adv Pharm Technol Res 7:22–6.
   PubMedGoogle Scholar
• Sheng B, Zhang J, Li R, et al. (2020). Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy. Am J Transl Res 12:5252–68.
   PubMed Web of Science ®Google Scholar
• Sosnik A. (2013). Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: a review. Adv Drug Deliv Rev 65:1828–51.
   PubMed Web of Science ®Google Scholar
• Subedi L, Pandey P, kang SH, et al. (2022). Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis. J Control Release 349:502–19.
   PubMed Web of Science ®Google Scholar
• Tan H, Zhou J, Yang X, et al. (2017). (99m)Tc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE(-/-) mice. Sci Rep 7:12.
   PubMed Web of Science ®Google Scholar
• Tiwari R, Pathak K. (2011). Statins therapy: a review on conventional and novel formulation approaches. J Pharm Pharmacol 63:983–98.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang L, He Y, et al. (2020). Atorvastatin and caffeine in combination regulates apoptosis, migration, invasion and tumorspheres of prostate cancer cells. Pathol Oncol Res 26:209–16.
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Lumb PJ, Semra Y, et al. (1999). Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 92:387–94.
   PubMed Web of Science ®Google Scholar
• Xiao H, Zhang Q, Lin Y, et al. (2008). Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122:2115–24.
   PubMed Web of Science ®Google Scholar
• Xie Y, Tan X, Huang J, et al. (2017). Atorvastatin-loaded micelles with bone-targeted ligand for the treatment of osteoporosis. Drug Deliv 24:1067–76.
   PubMed Web of Science ®Google Scholar
• Yang PM, Liu YL, Lin YC, et al. (2010). Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res 70:7699–709.
   PubMed Web of Science ®Google Scholar
• Zheng X, Cui XX, Gao Z, et al. (2010). Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila) 3:114–24.
   PubMed Web of Science ®Google Scholar